Ranibizumab vs Surabgene lomparvovec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Ranibizumab · Lucentis
Marketed by Roche and partners
NCT00056836 · Phase 3 · completed
The study was randomized and double-masked and enrolled 720 participants, but the registry does not identify the comparator arm or provide results. Because the primary clinical endpoint and whether it was met cannot be verified, the evidence remains limited despite the substantial trial size and controlled design.
Reported efficacy
Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Result source: NCT00056836
Surabgene lomparvovec
Developed by AbbVie and partners
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
Reported efficacy
RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)
Result source: NCT04832724
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Ranibizumab: 6 of 6 rows · Surabgene lomparvovec: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ranibizumab Rows use multiple source trials | Surabgene lomparvovec |
|---|---|---|
| BCVA Change Letters absolute change · ETDRS letters No placebo or comparator arm | 52.9 ETDRS letters @ 52wka,b,c,d NCT01914159 · Phase 2 · registry result, not featured evidence | -7.6 ETDRS letters @ 106wke,a,b,c,d NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more doses1.2 ETDRS letters @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence 14 ETDRS letters @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence 0.9 ETDRS letters @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence -3.8 ETDRS letters @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| CRT Change Microns absolute change · m No placebo or comparator arm | -158.9 m @ 104wke,f,g,c,h NCT01972789 · Phase 4 · registry result, not featured evidence show 1 more dose-126.9 m @ 104wk NCT01972789 · Phase 4 · registry result, not featured evidence | -88.6 m @ 106wke,f,g,c,h NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more doses25.3 m @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence 2 m @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence -56.7 m @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence -108.2 m @ 106wk NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Dropout rate | 10.7%i NCT02161575 · Phase 4 · registry result, not featured evidence show 51 more results23%0.5 mg NCT01846273 · Phase 4 · registry result, not featured evidence 13.1%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 0%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination —Intensive NCT01972789 · Phase 4 · registry result, not featured evidence 23%Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence 17.1%Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02140411 · Phase 4 · registry result, not featured evidence 4.8%Ranibizumab NCT02140411 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence 17.3%Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 6.5%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 6%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 20.4% NCT01810042 · Phase 4 · registry result, not featured evidence — NCT01464723 · Phase 4 · registry result, not featured evidence 9.1%50% Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 20%Ranibizumab NCT00473642 · Phase 4 · registry result, not featured evidence 20%Standard Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 5% NCT02611778 · Phase 3 · registry result, not featured evidence 10%0.5 mg monthly NCT01748292 · Phase 3 · registry result, not featured evidence 30%0.5 mg treat-and-extend NCT01748292 · Phase 3 · registry result, not featured evidence — NCT02698566 · Phase 3 · registry result, not featured evidence 10.2%0.5 mg treat-and-extend NCT01948830 · Phase 3 · registry result, not featured evidence 9.8%0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence n/a: no completion milestone0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence n/a: no completion milestone0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 4.4%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 6.2%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 5.5%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 5.8%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 22.2%Ranibizumab ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 11.3%Ranibizumab Non-ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 19.5%0.5 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 11.7%0.3 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 10.4%0.3 mg Monthly NCT00275821 · Phase 3 · registry result, not featured evidence 8.3%0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 10.7%0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 20%2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 25%2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 10.7%4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.2%2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 12.5% NCT01914159 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 5%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 21.1%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 0%Ranibizumab Group 1 NCT00896779 · Phase 2 · registry result, not featured evidence 8.3%Ranibizumab Group 2 NCT00896779 · Phase 2 · registry result, not featured evidence 3.3%1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination 3.4%0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination | 16.7%Cohort 1i NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results0%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 8.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.9%i NCT02161575 · Phase 4 · registry result, not featured evidence show 51 more results6.2%0.5 mg NCT01846273 · Phase 4 · registry result, not featured evidence 5.4%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 0%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination —Intensive NCT01972789 · Phase 4 · registry result, not featured evidence 6.3%Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence 2.3%Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02140411 · Phase 4 · registry result, not featured evidence 4.8%Ranibizumab NCT02140411 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence 1.2%Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 3%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 3%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence — NCT01810042 · Phase 4 · registry result, not featured evidence — NCT01464723 · Phase 4 · registry result, not featured evidence —50% Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination —Ranibizumab NCT00473642 · Phase 4 · registry result, not featured evidence —Standard Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 0.4% NCT02611778 · Phase 3 · registry result, not featured evidence 10%0.5 mg monthly NCT01748292 · Phase 3 · registry result, not featured evidence 10%0.5 mg treat-and-extend NCT01748292 · Phase 3 · registry result, not featured evidence — NCT02698566 · Phase 3 · registry result, not featured evidence 2.8%0.5 mg treat-and-extend NCT01948830 · Phase 3 · registry result, not featured evidence 0.6%0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence 0.6%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 1.2%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 0.7%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 0.7%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 0%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 0%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 5.6%Ranibizumab ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 5.8%Ranibizumab Non-ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 10.2%0.5 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 3.3%0.3 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 4.3%0.3 mg Monthly NCT00275821 · Phase 3 · registry result, not featured evidence —0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence —0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence —2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence —2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence —4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination —2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination — NCT01914159 · Phase 2 · registry result, not featured evidence —4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy —Ranibizumab Group 1 NCT00896779 · Phase 2 · registry result, not featured evidence —Ranibizumab Group 2 NCT00896779 · Phase 2 · registry result, not featured evidence —1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination | —Cohort 1i NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results—Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 10%i NCT02161575 · Phase 4 · registry result, not featured evidence show 51 more results17%0.5 mg NCT01846273 · Phase 4 · registry result, not featured evidence 15.7%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 14.3%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 33.5%Intensive NCT01972789 · Phase 4 · registry result, not featured evidence —Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence 33.3%Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence 28.6%0.5 mg NCT02140411 · Phase 4 · registry result, not featured evidence —Ranibizumab NCT02140411 · Phase 4 · registry result, not featured evidence 6.7%0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence —Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 14.5%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 14.5%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 4.1% NCT01810042 · Phase 4 · registry result, not featured evidence — NCT01464723 · Phase 4 · registry result, not featured evidence 0%50% Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 20%Ranibizumab NCT00473642 · Phase 4 · registry result, not featured evidence 0%Standard Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 8% NCT02611778 · Phase 3 · registry result, not featured evidence 35%0.5 mg monthly NCT01748292 · Phase 3 · registry result, not featured evidence 57.5%0.5 mg treat-and-extend NCT01748292 · Phase 3 · registry result, not featured evidence 0% NCT02698566 · Phase 3 · registry result, not featured evidence 12.1%0.5 mg treat-and-extend NCT01948830 · Phase 3 · registry result, not featured evidence 12.9%0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence 9%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 13.4%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 20.7%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 24.1%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 19.9%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 19.7%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 22.2%Ranibizumab ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 15.6%Ranibizumab Non-ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 19.5%0.5 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 12.5%0.3 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 17.4%0.3 mg Monthly NCT00275821 · Phase 3 · registry result, not featured evidence 0%0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 8%0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 0%2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 0%2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 14.3%4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.2%2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 0% NCT01914159 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 10%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 15.8%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 0%Ranibizumab Group 1 NCT00896779 · Phase 2 · registry result, not featured evidence 0%Ranibizumab Group 2 NCT00896779 · Phase 2 · registry result, not featured evidence —1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination 6.6%high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination 9.4%low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination | 33.3%Cohort 1i NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results33.3%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 25%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 33.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | i nasopharyngitis 9% cough 7% lower respiratory tract infection 7% NCT02161575 · Phase 4 · registry result, not featured evidence show 38 more results0.5 mg nasopharyngitis 7.4% dizziness 3.7% hypertension 3.7% NCT01846273 · Phase 4 · registry result, not featured evidence 0.5 mg + vPDT nasopharyngitis 13.4% retinal haemorrhage (study eye) 7% upper respiratory tract infection 7% NCT01846273 · Phase 4 · registry result, not featured evidence · combination 0.5 mg + vPDT intraocular pressure increased (study eye) 28.6% cerumen impaction 14.3% fasciitis 14.3% NCT01846273 · Phase 4 · registry result, not featured evidence · combination eye pain 16.2% influenza 15% influenza(non-ocular) 15% NCT01972789 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.7% nasopharyngitis(non-ocular) 16.7% eye pain 13.8% NCT01972789 · Phase 4 · registry result, not featured evidence 0.5 mg oedema peripheral 19% back pain 9.5% bronchitis 9.5% NCT02140411 · Phase 4 · registry result, not featured evidence 0.5 mg neovascular age-related macular degeneration 3.6% influenza 1.6% conjunctival haemorrhage 1.4% NCT01986907 · Phase 4 · registry result, not featured evidence 0.5 mg monthly nasopharyngitis 14.5% conjunctival haemorrhage 12.7% upper respiratory tract infection 8.4% NCT01775124 · Phase 4 · registry result, not featured evidence 0.5 mg PRN nasopharyngitis 10.8% conjunctival haemorrhage 7.2% intraocular pressure increased 7.2% NCT01775124 · Phase 4 · registry result, not featured evidence neovascular age-related macular degeneration 8% conjunctival haemorrhage 5.9% nasopharyngitis 5% NCT02611778 · Phase 3 · registry result, not featured evidence 0.5 mg monthly hollenhorst plaque 5% subretinal hemorrhage 5% progressive macular atrophy 0% NCT01748292 · Phase 3 · registry result, not featured evidence 0.5 mg treat-and-extend progressive macular atrophy 7.5% subretinal hemorrhage 2.5% hollenhorst plaque 0% NCT01748292 · Phase 3 · registry result, not featured evidence conjunctival hemorrhage 2.9% NCT02698566 · Phase 3 · registry result, not featured evidence 0.5 mg treat-and-extend intraocular pressure increased (study eye) 8.4% hypertension 7.1% nasopharyngitis 5.6% NCT01948830 · Phase 3 · registry result, not featured evidence 0.5 mg monthly intraocular pressure increased (study eye) 8.6% nasopharyngitis 8% conjunctival haemorrhage (study eye) 5.8% NCT01948830 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 7.2% conjunctival haemorrhage (study eye) 5.7% hypertension 5.4% NCT01780935 · Phase 3 · registry result, not featured evidence 0.5 mg intraocular pressure increased (study eye) 6.3% hypertension 4.5% influenza 4.5% NCT01780935 · Phase 3 · registry result, not featured evidence 0.5 mg as-needed (PRN) conjunctival haemorrhage 17.5% sinusitis 9.8% hypertension 7.6% NCT00891735 · Phase 3 · registry result, not featured evidence 0.5 mg monthly conjunctival haemorrhage 23% vitreous floaters 9.5% vitreous detachment 8% NCT00891735 · Phase 3 · registry result, not featured evidence 2.0 mg as-needed (PRN) conjunctival haemorrhage 15.1% vitreous detachment 9.9% eye pain 8.5% NCT00891735 · Phase 3 · registry result, not featured evidence 2.0 mg monthly conjunctival haemorrhage 18.6% eye pain 9.1% vitreous detachment 8.8% NCT00891735 · Phase 3 · registry result, not featured evidence retinal haemorrhage (study eye) 27.8% choroidal neovascularisation (fellow eye) 11.1% choroidal neovascularisation (study eye) 11.1% NCT00331864 · Phase 3 · registry result, not featured evidence visual acuity reduced (study eye) 18.3% intraocular pressure increased (study eye) 7% retinal haemorrhage (study eye) 6.8% NCT00331864 · Phase 3 · registry result, not featured evidence 0.5 mg - 3 Times Monthly, Then Quarterly conjunctival haemorrhage (study eye) 16.1% visual acuity reduced (study eye) 16.1% eye pain (study eye) 11.9% NCT00275821 · Phase 3 · registry result, not featured evidence 0.3 mg - 3 Times Monthly, Then Quarterly conjunctival haemorrhage (study eye) 19.2% eye pain (study eye) 18.3% visual acuity reduced (study eye) 12.5% NCT00275821 · Phase 3 · registry result, not featured evidence 0.3 mg Monthly eye pain (study eye) 20.9% intraocular pressure increased (study eye) 14.8% conjunctival haemorrhage (study eye) 10.4% NCT00275821 · Phase 3 · registry result, not featured evidence 0.5 mg monthly injection site irritation 4.5% corneal abrasion 0% NCT00764738 · Phase 2/3 · registry result, not featured evidence 0.5 mg PRN corneal abrasion 4% injection site irritation 4% NCT00764738 · Phase 2/3 · registry result, not featured evidence 4.0 mg conjunctival hyperaemia 14.3% (placebo 0%) eyelid oedema 10.7% (placebo 0%) retinal haemorrhage 10.7% (placebo 0%) NCT03211234 · Phase 2 · registry result, not featured evidence · combination 2.0 mg eye pain 12.9% (placebo 0%) conjunctival haemorrhage 9.7% (placebo 11.8%) retinal haemorrhage 9.7% (placebo 0%) NCT03211234 · Phase 2 · registry result, not featured evidence · combination increase of subretinal hemorrhage 4.2% NCT01914159 · Phase 2 · registry result, not featured evidence 4.0 mg iSONEP conjunctival haemorrhage 53.8% intraocular pressure increased 28.2% vitreous floaters 20.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.5 mg iSONEP conjunctival haemorrhage 60% activated partial thromboplastin time prolonged 12.5% vitreous floaters 12.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination conjunctival haemorrhage 34.2% retinal haemorrhage 28.9% arthralgia 7.9% NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy bruised sturnum 12.5% development of choroidal neovascularization - fellow eye 12.5% intestinal flu 12.5% NCT00896779 · Phase 2 · registry result, not featured evidence ache left eye - treatment eye 8.3% cold 8.3% corneal abrasion - both eyes 8.3% NCT00896779 · Phase 2 · registry result, not featured evidence high dose conjunctival hemorrhage 33.6% punctate keratitis 9.9% conjunctival hyperemia 8.6% NCT01089517 · Phase 2 · registry result, not featured evidence · combination low dose conjunctival hemorrhage 22.8% punctate keratitis 12.8% eye pain 6.7% NCT01089517 · Phase 2 · registry result, not featured evidence · combination | i intraocular inflammation 66.7% retinal haemorrhage 66.7% visual acuity reduced/impairment 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more resultsconjunctival haemorrhage 50% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 66.7% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100% conjunctival haemorrhage 75% retinal thickening 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 91.7% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7% eye irritation 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 1/2 versus Phase 2.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 106 weeks versus 52 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 1/2 versus Phase 4.
- gPopulation comparability has not been reviewed for both studies.
- hAssessment timepoints differ: 106 weeks versus 104 weeks.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ranibizumab
show 25 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 58 further endpoints in the CSV export.
Surabgene lomparvovec
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ranibizumab's landscape · Surabgene lomparvovec's landscape